Lee Hyun Young, Pyun Jong Hyun, Shim Sung Ryul, Kim Jae Heon
Department of Urology, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea.
Department of Urology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
World J Mens Health. 2024 Jan;42(1):133-147. doi: 10.5534/wjmh.230016. Epub 2023 Jun 15.
To investigate the efficacy of medical treatment options for Peyronie's disease (PD) including oral drugs, intralesional treatment and mechanical treatment compared with placebo treatment using network meta-analysis (NMA).
We searched the randomized controlled trials (RCTs) of PD in PubMed, Cochrane library, and EMBASE up to October 2022. RCTs included medical treatment options: oral drugs, intralesional treatment and mechanical treatment. Studies reporting at least one of the outcome measures of interest including curvature degree, plaque size, and structured questionnaires (International Index of Erectile Function, IIEF) were included.
Finally, 24 studies including 1,643 participants met our selection criteria for NMA. There was no statistically significant treatment compared to placebo of the curvature degree, plaque size, IIEF in Bayesian analysis. The SUCRA values of ranking probabilities for each treatment performance, which indicated that hyperthermia device ranked first in NMA. However, in frequentist analysis, 7 of mono treatments (coenzyme Q10 [CoQ10] 300 mg, hyperthermia device, interferon alpha 2b, pentoxifylline 400 mg, propionyl-L-carnitine 1 g, penile traction therapy [PTT], vitamin E 300 mg) and 2 of combination treatments ("PTT-extracorporeal shockwave treatment", "vitamin E 300 mg-propionyl-L-carnitine 1 g") were statistically significant for improvement of curvature degree, and 9 of mono treatments (CoQ10 300 mg, hyaluronic acid 16 mg, hyperthermia device, interferon alpha 2b, pentoxifylline 400 mg, propionyl-L-carnitine 1 g, verapamil 10 mg, vitamin E 300 mg, vitamin E 400 U) and 3 of combination treatments ("interferon alpha 2b-vitamin E 400 U", "verapamil 10 mg-antioxidants", "vitamin E 300 mg-propionyl-L-carnitine 1 g") were statistically significant in the improvement of plaque size.
At present, there is no clinical treatment alternatives that have been demonstrated to be effective compared to placebo. Nonetheless, as the frequentist approach has shown that a number of agents are efficacious, further research is expected to develop more effective treatment options.
采用网状Meta分析(NMA),比较口服药物、病灶内治疗和机械治疗等佩罗尼氏病(PD)的医学治疗方案与安慰剂治疗的疗效。
我们检索了截至2022年10月在PubMed、Cochrane图书馆和EMBASE中关于PD的随机对照试验(RCT)。RCT包括医学治疗方案:口服药物、病灶内治疗和机械治疗。纳入报告了至少一项感兴趣的结局指标的研究,这些指标包括弯曲度、斑块大小和结构化问卷(国际勃起功能指数,IIEF)。
最终,24项研究(共1643名参与者)符合我们NMA的纳入标准。在贝叶斯分析中,与安慰剂相比,弯曲度、斑块大小、IIEF的治疗均无统计学显著差异。每种治疗效果的排序概率的累积排序曲线下面积(SUCRA)值表明,热疗设备在NMA中排名第一。然而,在频率学派分析中,7种单一治疗(辅酶Q10[CoQ10]300mg、热疗设备、干扰素α2b、己酮可可碱400mg、丙酰-L-肉碱1g、阴茎牵引治疗[PTT]、维生素E 300mg)和2种联合治疗(“PTT-体外冲击波治疗”、“维生素E 300mg-丙酰-L-肉碱1g”)在改善弯曲度方面有统计学显著差异,9种单一治疗(CoQ10 300mg、透明质酸16mg、热疗设备、干扰素α2b、己酮可可碱400mg、丙酰-L-肉碱1g、维拉帕米10mg、维生素E 300mg、维生素E 400U)和3种联合治疗(“干扰素α2b-维生素E 400U”、“维拉帕米10mg-抗氧化剂”、“维生素E 300mg-丙酰-L-肉碱1g”)在改善斑块大小方面有统计学显著差异。
目前,尚无已证实比安慰剂更有效的临床治疗方案。尽管如此,由于频率学派方法表明一些药物有效,预计进一步的研究将开发出更有效的治疗方案。